The UAE insurance sector continued to grow in Q4-2023, as reflected by increase in the gross written premiums. As of year-end, the number of licensed insurance companies in the UAE remained at 60, according to the Central Bank of the UAE's (CBUAE) Quarterly Economic Review (Q4-2023). The insurance sector comprised 23 traditional national companies, 10 Takaful national and 27 foreign companies, while the number of insurance related professions remained at 491. The review on insurance sector structure and activity showed that the gross written premium increased by 12.7% Y-o-Y in Q4 2023 to AED 53.2 billion, mostly due to an increase in health insurance premiums by 16.5% Y-o-Y and an increase in property and liability insurance premiums by 18.9% Y-o-Y, while the insurance of persons and fund accumulation premiums decreased by 12.4% Y-o-Y, resulting primarily from decrease in individual life premiums. Gross paid claims of all types of insurance plans increased by 12.8% Y-o-Y to AED 31.1 billion at the end of 2023. This was mainly driven by the increase in claims paid in health insurance by 16.9% Y-o-Y and increase in paid claims in property and liability insurance by 10.9% Y-o-Y, partially offset by the decline in claims paid in insurance of persons and fund accumulation by 2.8% Y-o-Y. The total technical provisions of all types of insurance increased by 8.4% Y-o-Y to AED 74.4 billion in Q4 2023 compared to AED68.6 billion in Q4 2022. The volume of invested assets in the insurance sector amounted to AED 76 billion (60.4% of total assets) in Q4 2023 compared to AED 71.4 billion (59.4% of total assets) in Q4 2022. The retention ratio of written insurance premiums for all types of insurance was 52.9 % (AED 28.1 billion) in Q4 2023, compared to 54.9% (AED 25.9 billion) at the end of 2022. The UAE insurance sector remained well capitalized in terms of early warning ratios and risk assessment. Own funds to minimum capital requirement ratio increased to 335.7% in Q4 2023, compared to 309.3% at the end of 2022, due to an increase in own funds eligible to meet the minimum capital requirements. Also, own funds to solvency capital requirement ratio rose to 221% in Q4 2023 compared to 208.5% in Q4 2022, due to an increase in own funds eligible to meet solvency capital requirements. Finally, own funds to minimum guarantee fund ratio reached to 316.3% at the end of 2023 down from 314.6% a year earlier, due to higher eligible funds to meet minimum guarantee funds. In terms of profitability, the net total profit to net written premiums increased to 6.5% in Q4 2023, compared to 2.9% at the end of 2022. The return on average assets increased to 0.3% in Q4 2023 compared to the 0.1% at the of the previous year.

White House spokeswoman Karina Jean-Pierre denied a report in the U.S. media on the 8th that President Joseph Biden did not receive treatment for Parkinson's disease. Biden had the first televised debate of the 2024 presidential election with Republican opponent Donald Trump on June 27, and his poor performance on the spot triggered discussions about his physical condition. The New York Times reported that a doctor specializing in the treatment of Parkinson's disease had "visited" the White House eight times from August last year to March this year. Facing the media's questions about Biden's health, Jean-Pierre asked and answered himself at a regular White House press conference on the 8th: "Has the president received treatment for Parkinson's disease? No. Is he currently receiving treatment for Parkinson's disease? No, he is not. Is he taking medication for Parkinson's disease? No." Jean-Pierre said Biden had seen a neurologist three times, all related to his annual physical examination. She also took out the report issued by the doctor after Biden's most recent physical examination in February this year. The report said, "An extremely detailed neurological examination was once again reassuring" because no symptoms consistent with stroke, multiple sclerosis or Parkinson's disease were found. The doctor who went to the White House mentioned by the New York Times is Kevin Kanal, a neurology and movement disorder expert at the Walter Reed National Military Medical Center in Maryland and an authority on Parkinson's disease. Jean-Pierre suggested that the doctor might have come to treat military personnel on duty at the White House.

On Monday, executives from the three major chip giants in the US - Intel, Qualcomm, and Nvidia - met with US officials, including Antony Blinken, to voice their opposition to the Biden administration's plan of imposing further restrictions on chip sales to Chinese companies and investments in China. The Semiconductor Industry Association also released a similar statement, opposing the exclusion of US semiconductor companies from the Chinese market. First of all, we mustn't believe that the appeals of these companies and industry associations will collectively change the determination of US political elites to stifle China's progress. These US elites are very fearful of China's rapid development, and they see "chip chokehold" as a new discovery and a successful tactic formed under US leadership and with the cooperation of allies. Currently, the chip industry is the most complex technology in human history, with only a few companies being at the forefront. They are mainly from the Netherlands, Taiwan island, South Korea, and Japan, most of which are in the Western Pacific. These countries and regions are heavily influenced by the US. Although these companies have their own expertise, they still use some American technologies in their products. Therefore, Washington quickly persuaded them to form an alliance to collectively prevent the Chinese mainland from obtaining chips and manufacturing technology. Washington is proud of this and wants to continuously tighten the noose on China. The New York Times directly titled an article "'An Act of War': Inside America's Silicon Blockade Against China, " in which an American AI expert, Gregory Allen, publicly claimed that this is an act of war against China. He further stated that there are two dates that will echo in history from 2022: The first is February 24, when the Russia-Ukraine conflict broke out, and the second is October 7, when the US imposed a sweeping set of export controls on selling microchips to China. China must abandon its illusions and launch a challenging and effective counterattack. We already have the capability to produce 28nm chips, and we can use "small chip" technology to assemble small semiconductors into a more powerful "brain," exploring 14nm or even 7nm. Additionally, China is the world's largest commercial market for commodity semiconductors. Last year, semiconductor procurement in China amounted to $180 billion, surpassing one-third of the global total. In the past, China had been faced with the choice between independent innovation and external purchases. Due to the high returns from external purchases, it is easy for it to become the overwhelming choice over independent research and development. However, now the US is gradually blocking the option of external purchases, and China has no strategic choice but to independently innovate, which in turn puts tremendous pressure on American companies. Scientists generally expect that, although China may take some detours, such as recently apprehending several company leaders who fraudulently obtained subsidies from national semiconductor policies, China has the ability to gradually overcome the chip difficulties. And we will form our own breakthroughs and industrial chain, which is expected to put quite a lot of pressure on US companies. If domestic firms acquire half of China's $180 billion per year in chip acquisitions, this would provide a significant boost for the industry as a whole and help it advance steadily. The New York Times refers to the battle on chips as a bet by Washington. "If the controls are successful, they could handicap China for a generation; if they fail, they may backfire spectacularly, hastening the very future the United States is trying desperately to avoid," it argued. Whether it is a war or a game, when the future is uncertain, what US companies hope for most of all is that they can sell simplified versions of high-end chips to China, so that the option of external purchases by China continues to exist and remains attractive. This can not only maintain the interests of the US companies, enabling them to obtain sufficient funds to develop more advanced technologies, but also disrupt China's plans for independent innovation. This idea is entirely based on their own commercial interests and also has a certain political and national strategic appeal. Hence, there is no shortage of supporters within the US government. US Secretary of the Treasury Janet Yellen seems to be one of them, as she has repeatedly stated that the US' restrictions on China will not "fundamentally" hurt China, but will only be "narrowly targeted." The US will balance its strict suppression on China from the perspective of maintaining its technological hegemony, while also leaving some room for China, in order to undermine China's determination to counterattack in terms of independent innovation. China needs to use this mentality of the US to its advantage. On the one hand, China should continue to purchase US chips to maintain its economic fundamentals, and on the other hand, it should firmly support the development of domestic semiconductor companies from both financial and market perspectives. If China were to continue relying on exploiting the gaps in US chip policies in the long term, akin to a dependency on opium, it would only serve to weaken China further as it becomes increasingly addicted. China's market is extremely vast, and its innovation capabilities are generally improving and expanding. Although the chip industry is highly advanced, if there is one country that can win this counterattack, it is China. As long as we resolutely continue on the path of independent innovation, this road will definitely become wider. Various breakthroughs and turning points that are unimaginable today may soon occur.

This Barbie is going to be a mother. And Margot Robbie has no problem putting her burgeoning baby bump on full display. In fact, the Barbie star, who is pregnant with her Tom Ackerley’s first baby, debuted recently her bump while vacationing on Italy’s Lake Como with her husband July 7. For the outing, Margot donned a black blazer over a white tee that was cropped above her stomach, showing off a sweet baby bump. She finished off the look with low-rise black trousers, black platform sandals and a summery straw bag. For his part, Tom—whom Margot wed in a 2016 ceremony in her native Australia—wore olive green trousers and a cream-colored button-down shirt and tan sneakers. The couple were photographed waiting on a dock in Lake Como before they hopped in a boat and sailed off into a literal sunset. While Margot and Tom, both 34, haven’t spoken publicly about their upcoming bundle of joy, the I, Tonya alum has previously expressed hope to have a big family one day. As she told Porter in 2018, “If I'm looking into my future 30 years from now, I want to see a big Christmas dinner with tons of kids there.” Tom and Margot’s new chapter comes over ten years after their love story first began on the set of 2014's Suite Française, in which Margot starred while Tom worked as a third assistant director. But while she was immediately smitten, Margot was convinced her love would go unrequited. "I was always in love with him, but I thought, ‘Oh, he would never love me back,'" she admitted to Vogue in 2016. "'Don't make it weird, Margot. Don't be stupid and tell him that you like him.' And then it happened, and I was like, ‘Of course we're together. This makes so much sense, the way nothing has ever made sense before.'"

According to AndroidAuthority, the Linux kernel used by Android devices is mostly derived from Google's Android Universal Kernel (ACK) branch, which is created from the Android mainline kernel branch when new LTS versions are released upstream. For example, when kernel version 6.6 is announced as the latest LTS release, an ACK branch for Android15-6.6 appears shortly after, with the "android15" in the name referring to the Android version of the kernel (in this case, Android 15). Google maintains its own set of LTS kernel branches for three main reasons. First, Google can integrate upstream features that have not yet been released into the ACK branch by backporting or picking, so as to meet the specific needs of Android. Second, Google can include some features that are being developed upstream in the ACK branch ahead of time, making it available for Android devices as early as possible. Finally, Google can add some vendor or original equipment manufacturer (OEM) features for other Android partners to use. Once created, Google continues to update the ACK branch to include not only bug fixes for Android specific code, but also to integrate the LTS merge content of the upstream kernel branch. For example, the Linux kernel vulnerability disclosed in the July 2024 Android security bulletin will be fixed through these updates. However, it is not easy to distinguish a bug fix from other bug fixes, as a patch that fixes a bug may also accidentally plug a security vulnerability that the submitter did not know about or chose not to disclose. Google does its best to recognize this, but it inevitably misses the mark, resulting in bug fixes for the upstream Linux kernel being released months before Android devices. As a result, Google has been urging Android vendors to regularly update the LTS kernel to avoid being caught off guard by unexpectedly disclosed security vulnerabilities. Clearly, the LTS version of the Linux kernel is critical to the security of Android devices, helping Google and vendors deal with known and unknown security vulnerabilities. The longer the support period, the more timely security updates Google and vendors can provide to devices.